Overview
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company based in the United States, specifically headquartered in Pasadena, California. It operates primarily within the healthcare sector, focusing on developing medicines that treat intractable diseases by silencing the genes that cause them. Arrowhead’s research and development strategy involves leveraging its proprietary RNA interference (RNAi) technology to create drugs that precisely silence or eliminate genetic expressions contributing to disease processes. Notable projects include therapies targeting various diseases such as AAT liver disease, chronic hepatitis B, and inherited diseases with limited treatment options. The company's innovative approach reflects a broader trend in biotech towards targeted genetic interventions.
Basic Stats
The Factor Analysis chart (below right) shows a view of Arrowhead Pharmaceuticals, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 103.19 MM |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | 0.00 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | 0.00 |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 0.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Arrowhead Pharmaceuticals, Inc. is MX$78.80. The forecasts range from a low of MX$39.39 to a high of MX$115.50. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
| Record Date | Projection Date | High | Low | Median | Average |
|---|---|---|---|---|---|
| 2023-04-02 | 2024-04-02 | 115.50 | 39.39 | 82.11 | 78.80 |
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Arrowhead Pharmaceuticals, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2024-09-09 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2024-09-05 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-12 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-11 | RBC Capital | Outperform | Outperform | Reiterate |
| 2025-02-11 | Chardan Capital | Buy | Buy | Maintains |
| 2024-10-11 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-14 | B. Riley Securities | Buy | Buy | Reiterate |
| 2025-05-13 | Citigroup | Neutral | Neutral | Maintains |
| 2025-05-13 | Chardan Capital | Buy | Buy | Maintains |
| 2024-07-17 | Chardan Capital | Buy | Buy | Maintains |
| 2024-07-05 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-06-26 | Chardan Capital | Buy | Buy | Maintains |
| 2024-06-20 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2024-06-11 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-06-05 | Goldman Sachs | Neutral | Initiate | |
| 2024-06-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-06-03 | Chardan Capital | Buy | Buy | Maintains |
| 2024-05-13 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-13 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-05-10 | Chardan Capital | Buy | Buy | Maintains |
| 2024-02-08 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-02-07 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-02-07 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-02-07 | Citigroup | Neutral | Neutral | Maintains |
| 2024-01-16 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-01-02 | B of A Securities | Buy | Buy | Maintains |
| 2023-12-04 | B of A Securities | Buy | Initiate | |
| 2023-11-30 | RBC Capital | Outperform | Outperform | Reiterate |
| 2023-11-30 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-09-19 | Citigroup | Neutral | Initiate | |
| 2023-08-09 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-08-08 | RBC Capital | Outperform | Outperform | Reiterate |
| 2023-08-08 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2023-08-08 | Chardan Capital | Buy | Buy | Reiterate |
| 2023-07-21 | TD Cowen | Outperform | Initiate | |
| 2023-07-20 | B. Riley Securities | Buy | Buy | Reiterate |
| 2023-06-30 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-06-06 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-06-02 | Piper Sandler | Overweight | Overweight | Maintains |
| 2023-06-02 | Chardan Capital | Buy | Buy | Reiterate |
| 2023-05-24 | Chardan Capital | Buy | Buy | Reiterate |
| 2023-05-12 | SVB Leerink | Outperform | Market Perform | Downgrade |
| 2023-05-03 | RBC Capital | Outperform | Reiterate | |
| 2023-05-03 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-05-03 | Goldman Sachs | Buy | Maintains | |
| 2023-04-26 | SMBC Nikko | Outperform | Initiate | |
| 2023-04-12 | SVB Securities | Market Perform | Outperform | Upgrade |
| 2023-03-21 | Bernstein | Market Perform | Initiate | |
| 2023-02-10 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-02-10 | Chardan Capital | Buy | Reiterate | |
| 2023-02-08 | B. Riley Securities | Buy | Maintains | |
| 2023-02-07 | RBC Capital | Outperform | Maintains | |
| 2023-02-07 | Baird | Outperform | Maintains | |
| 2023-02-07 | Piper Sandler | Overweight | Maintains | |
| 2022-12-06 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-11-30 | B. Riley Securities | Buy | Maintains | |
| 2022-11-29 | Jefferies | Buy | Maintains | |
| 2022-11-29 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-11-29 | SVB Leerink | Market Perform | Maintains | |
| 2022-11-10 | Piper Sandler | Overweight | Maintains | |
| 2022-11-10 | SVB Leerink | Market Perform | Maintains | |
| 2022-09-09 | Morgan Stanley | Equal-Weight | Initiate | |
| 2022-08-08 | Goldman Sachs | Buy | Maintains | |
| 2022-06-03 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-05-24 | Goldman Sachs | Buy | Maintains | |
| 2022-05-11 | Chardan Capital | Buy | Maintains | |
| 2022-05-11 | Piper Sandler | Overweight | Maintains | |
| 2022-05-11 | Baird | Neutral | Outperform | Upgrade |
| 2022-05-11 | SVB Leerink | Market Perform | Maintains | |
| 2022-02-03 | SVB Leerink | Market Perform | Maintains | |
| 2022-01-28 | SVB Leerink | Market Perform | Maintains | |
| 2022-01-19 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2021-11-23 | SVB Leerink | Market Perform | Maintains | |
| 2021-08-10 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-08-06 | Chardan Capital | Buy | Maintains | |
| 2021-02-08 | B. Riley FBR | Buy | Maintains | |
| 2021-02-05 | Piper Sandler | Overweight | Maintains | |
| 2021-02-05 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-02-05 | Chardan Capital | Buy | Maintains | |
| 2020-12-21 | Baird | Outperform | Neutral | Downgrade |
| 2020-11-24 | SVB Leerink | Market Perform | Maintains | |
| 2020-11-19 | Citigroup | Buy | Initiate | |
| 2020-09-17 | SVB Leerink | Market Perform | Maintains | |
| 2020-05-13 | RBC Capital | Outperform | Initiate | |
| 2020-05-08 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2020-04-15 | Cantor Fitzgerald | Neutral | Overweight | Upgrade |
| 2020-03-24 | SVB Leerink | Underperform | Market Perform | Upgrade |
| 2020-03-17 | Goldman Sachs | Neutral | Initiate | |
| 2020-03-13 | B. Riley FBR | Buy | Maintains | |
| 2020-02-06 | Cantor Fitzgerald | Neutral | Maintains | |
| 2020-01-21 | SVB Leerink | Underperform | Initiate | |
| 2019-12-13 | Oppenheimer | Perform | Initiate | |
| 2019-11-25 | Baird | Neutral | Outperform | Upgrade |
| 2019-11-19 | Cantor Fitzgerald | Neutral | Maintains | |
| 2019-11-13 | B. Riley FBR | Buy | Maintains | |
| 2019-10-24 | Baird | Outperform | Neutral | Downgrade |
| 2019-10-22 | Chardan Capital | Buy | Maintains | |
| 2019-10-03 | Baird | Outperform | Initiate | |
| 2019-08-19 | B. Riley | Buy | Maintains | |
| 2019-06-28 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| 2018-12-17 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2018-09-06 | B. Riley FBR | Neutral | Buy | Upgrade |
| 2018-09-06 | Chardan Capital | Buy | Buy | Maintains |
| 2018-08-08 | B. Riley FBR | Neutral | Neutral | Maintains |
| 2018-05-09 | Cantor Fitzgerald | Neutral | Overweight | Upgrade |
| 2018-03-27 | Jefferies | Buy | Initiate | |
| 2018-02-12 | Cantor Fitzgerald | Hold | Neutral | Maintains |
| 2018-02-12 | B. Riley | Neutral | Neutral | Maintains |
| 2018-01-05 | B. Riley FBR | Neutral | Initiate | |
| 2018-01-05 | B. Riley | Neutral | Initiate | |
| 2017-11-27 | PiperJaffray | Neutral | Overweight | Upgrade |
| 2017-09-18 | William Blair | Market Perform | Outperform | Upgrade |
| 2016-11-30 | William Blair | Outperform | Market Perform | Downgrade |
| 2016-11-30 | Cantor Fitzgerald | Buy | Hold | Downgrade |
| 2016-11-30 | PiperJaffray | Overweight | Neutral | Downgrade |
| 2016-11-30 | Jefferies | Hold | Maintains | |
| 2016-11-30 | Chardan Capital | Buy | Neutral | Downgrade |
| 2016-08-18 | Cantor Fitzgerald | Buy | Initiate | |
| 2016-05-19 | Chardan Capital | Buy | Initiate | |
| 2015-09-25 | PiperJaffray | Overweight | Maintains | |
| 2015-04-14 | Jefferies | Buy | Hold | Downgrade |
| 2015-01-22 | Deutsche Bank | Buy | Hold | Downgrade |
| 2014-10-09 | RBC Capital | Outperform | Sector Perform | Downgrade |
| 2014-10-08 | Deutsche Bank | Buy | Maintains | |
| 2014-03-05 | Deutsche Bank | Buy | Initiate | |
| 2014-03-05 | RBC Capital | Outperform | Initiate | |
| 2014-03-04 | RBC Capital | Outperform | Initiate | |
| 2014-03-03 | Barclays | Overweight | Initiate | |
| 2013-12-18 | Jefferies | Buy | Initiate | |
| 2013-10-21 | PiperJaffray | Overweight | Initiate | |
| 2013-02-26 | Dawson James | Buy | Initiate | |
| 2024-07-23 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-26 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-12-03 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-11-29 | Bernstein | Market Perform | Market Perform | Maintains |
| 2024-11-27 | Citigroup | Neutral | Neutral | Maintains |
| 2024-11-27 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-11-27 | Chardan Capital | Buy | Buy | Maintains |
| 2024-11-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-12-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-12-12 | Chardan Capital | Buy | Buy | Maintains |
| 2024-10-08 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2025-01-23 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-22 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-12 | B. Riley Securities | Buy | Buy | Reiterate |
| 2025-08-08 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-09-02 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-05-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-08-11 | Chardan Capital | Buy | Buy | Maintains |
